Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.

Lung cancer screening via annual low-dose computed tomography has poor adoption. We conducted a prospective case-control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung cancer detection test that when positive is followed by a low-dose computed tomography. Changes in genome-wide cell-free DNA fragmentation profiles (fragmentomes) in peripheral blood reflected genomic and chromatin characteristics of lung cancer.

Value of next generation sequencing (NGS) testing in advanced cancer patients.

Objective: The availability of targeted therapies for oncology patients is increasing. Available genomic tests to identify treatment-eligible patients include single gene tests and gene panel tests, including the whole-exome, whole-transcriptome OncoExTra test. We assessed the costs and clinical benefits of test choice.

Reduced mortality, complications, and economic burden among medicare beneficiaries receiving influenza antivirals.

Introduction: Antiviral therapy may be underutilized in patients at high risk for increased clinical and economic burden (e.g. older adults).

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide.

Purpose: Multiple sclerosis (MS) is a costly, immune-mediated disease of the central nervous system. Most patients have relapsing-remitting MS (RRMS) for which disease-modifying therapies (DMTs) provide an effective treatment option by reducing relapse rates. However, adherence to DMTs is suboptimal.

In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database.

Describe the clinical and economic burden of hospitalizations for amyloid light chain (AL) amyloidosis. This retrospective analysis used nationally representative hospital discharge data (2017-2020) to report discharge status, resource use and costs for hospitalizations among patients with AL amyloidosis. Of 1341 patients identified, 92% were discharged alive and 8% experienced in-hospital death.